Industry News (Lung Cancer Therapy)

Oral Anti-Angiogenesis Drug Trial To Treat Cancer Announced

Published in Cancer Weekly, August 30th, 1999

Agouron Pharmaceuticals, Inc., La Jolla, California, announced that it has initiated a second Phase III clinical trial of the matrix metalloprotease (MMP) inhibitor prinomastat (formerly AG3340) in combination with chemotherapy in patients with advanced non-small cell lung cancer.

In preclinical models, prinomastat has been shown to potently inhibit angiogenesis, tumor invasion, and metastasis. This trial is designed to evaluate the safety and efficacy of prinomastat as part of first-line therapy in combination with chemotherapy, an effort led by ongoing Phase III clinical trials. This trial advances the ongoing clinical development of prinomastat in combination with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-08-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry